Biotechnology
Harbour BioMed to Present Phase II Data of HBM4003 and Tislelizumab Combination in MSS Metastatic Colorectal Cancer at ESMO 2025
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 29, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that it will present Phase II ...
2025-07-30 08:01
3008
XellSmart Completed World's First Patient Dosing in its Registrational Clinical trial for iPSC-derived Subtype-specific Neural Cell Therapy for Spinal Cord Injury
SUZHOU, China, July 28, 2025 /PRNewswire/ -- XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd. achieved a significant milestone in its "world's first" China NMPA & US FDA-approved registrational clinical trial. This Phase I China registrational clinical trial for XS228 Cell Injection – the ...
2025-07-28 21:10
4320
World's First Engineered Exosome for Hair Growth & Localized Fat Reduction Secure INCI Designation: ImmVira Accelerates Access to Billion-Dollar Aging-related Market
SUZHOU, China, July 28, 2025 /PRNewswire/ -- ImmVira Group ("ImmVira" or the "Company")recently announced that its engineered exosome products MVR-EX104 ("EX104", for alopecia treatment) and MVR-EX105 ("EX105", for localized fat accumulation) have obtained International Nomenclature of Cosmetic I...
2025-07-28 20:28
4333
Harbour BioMed Announces Positive Profit Alert for 2025 Interim Results
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 27, 2025 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a positive prof...
2025-07-28 08:11
3131
Angel Yeast Showcases Innovative Yeast Protein at 2025 IFT FIRST in Chicago
CHICAGO, July 24, 2025 /PRNewswire/ -- The 2025 IFT FIRST (Food Improved by
Research, Science, and Technology), one of the world's largest food science and
innovation expos, recently took place fromJuly 13 to 16 in Chicago. At the expo,
Angel Yeast
2025-07-24 21:00
3509
OSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring Technology
BELLEVUE, Wash. and SEOUL, South Korea, July 24, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical and wellness innovation, today announced it has signed a term sheet ("Term Sheet") with Woori IO Co., Ltd. ("WORIO"), a South Korean medical de...
2025-07-24 19:30
3829
Fapon at ADLM 2025: One-stop IVD Solutions & Deepened US Commitment
CHICAGO, July 24, 2025 /PRNewswire/ -- Fapon, a global leader in life sciences, will unveil its innovative one-stop IVD solutions at ADLM 2025, fromJuly 29 to 31 in Chicago, IL. Fapon aims to be the trusted global partner for laboratories and IVD manufacturers with advanced innovations and dedica...
2025-07-24 19:00
2876
HBM9378/WIN378, a Long-Acting, Fully Human Anti-TSLP Antibody, Enters Global Phase 2 POLARIS Trial for Asthma
* Phase 2 POLARIS trial will evaluate the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma, with an initial data readout expected in mid-2026 * HBM9378/WIN378 has the potential to be the first-to-market long-acting anti-TSLP antibody with twice-yearly dosing for asthma ...
2025-07-23 20:36
3045
Samsung Biologics reports second quarter 2025 financial results
* Recorded Q2'25 consolidated revenue of KRW 1,289.9 billion * Recorded Q2'25 consolidated operating profit of KRW 475.6 billion * Solid momentum sustained through capacity ramp-up and stable project execution INCHEON, South Korea, July 23, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940...
2025-07-23 14:54
3391
METiS Technologies Showcases AI-Powered Nanodelivery Platform at the 2025 Controlled Release Society Annual Meeting
HANGZHOU, BEIJING, China and CAMBRIDGE, Mass., July 22, 2025 /PRNewswire/ -- METiS Technologies, a global leader in AI-driven nanodelivery innovation, today announced the presentation of its latest research findings at the poster session of the 2025 Controlled Release Society (CRS) Annual Meeting...
2025-07-22 15:52
4345
DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation
SHANGHAI, July 21, 2025 /PRNewswire/ -- DualityBio (HKEX Stock Code: 9606.HK) announced thatthe U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its next-generation HER3-targeting antibody-drug conjugate (ADC) DB-1310. This designation is for the treatment of ad...
2025-07-22 10:25
3787
CorestemChemon Expands Global CRO Reach with ATG Lifetech, Targeting Next-Gen Preclinical Services
Strategic partnership to deliver transcriptomics-powered, organoid-based preclinical testing for high-impact drug discovery SEOUL, South Korea, July 20, 2025 /PRNewswire/ -- CorestemChemon, a leading GLP-certified preclinical CRO based inSouth Korea, has entered into a strategic partnership wit...
2025-07-21 10:54
2690
MFDS Clears DeepQure's HyperQure™ for Clinical Trial in Atrial Fibrillation
SEOUL, South Korea, July 17, 2025 /PRNewswire/ -- DeepQure announced today that South Korea's Ministry of Food and Drug Safety (MFDS) has approved a clinical trial of HyperQure™ RDM System, the company's novel laparoscopic renal denervation (RDN) system, for the treatment of atrial fibrillation (...
2025-07-18 10:59
3186
Co-PSMA trial: Recruitment successfully completed
SYDNEY, July 17, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Co-PSMA (NCT...
2025-07-17 21:01
4550
SK bioscience Submits IND for Phase 1/2 Clinical Trial of Adjuvanted Influenza Vaccine Candidate
* Company aims for technology advancement and platform expansion with Korea's first influenza vaccine using an adjuvant * Interim results from the Phase 1/2 trial expected by 2027, aimed at entering the high-immunogenicity vaccine market * "Our SKYCellflu platform with our adjuvanted vaccine...
2025-07-17 19:00
3485
GC Biopharma Receives Marketing Authorization for BARYCELA in Vietnam
YONGIN, South Korea, July 17, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean pharmaceutical company, announced that its varicella vaccine BARYCELA has received marketing authorization from the Drug Administration of Vietnam (DAV). Following domestic approval in 2020 and WHO Pre-Q...
2025-07-17 13:56
2552
SNB-101 Earns Government Backing as Promising Therapy for Small Cell Lung Cancer
SEONGNAM, South Korea, July 16, 2025 /PRNewswire/ -- In a strong endorsement of its cutting-edge drug delivery technology, SN BioScience announced that its anticancer candidate SNB-101 has been selected as a clinical-stage project under the 2025 Korea Drug Development Project, a government-initia...
2025-07-16 20:00
3532
The 2025 Mammoth International Contest on Omics Sciences - Young Scientists Track Now Open for Hot Registration!
SHENZHEN, China, July 16, 2025 /PRNewswire/ -- Under the guidance of UNESCO and the United Nations International Cooperation Public Welfare Organization, the 2025 Mammoth International Contest on Omics Sciences - Young Scientist Track (referred to as 2025 MICOS-Youth), co-organized by BGI Researc...
2025-07-16 18:12
2437
WuXi Biologics Granted Highest Negligible-Risk ESG Rating from Morningstar Sustainalytics
* Best ESG rating tier of negligible-risk with a top 1% global ranking score * Industry and Regional ESG Top-Rated Company for five consecutive years * Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, July 16, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading ...
2025-07-16 18:00
2723
Senhwa Biosciences announces first patient dosed in NCI-sponsored pilot study of Pidnarulex (CX-5461) pharmacodynamics in patients with advanced solid tumors
TAIPEI and SAN DIEGO, July 15, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that its new drug Pidnarulex (CX-5461) has been selected by the U...
2025-07-16 10:32
3105
Week's Top Stories
Most Reposted
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
[Picked up by 310 media titles]
2026-10-13 10:00
Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 278 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 275 media titles]
2026-10-09 13:21DayOne Upsizes Malaysia Financing to US$7.2 Billion; Total Billings Surpass 1GW and Bookings Reach 2.3GW
[Picked up by 269 media titles]
2026-10-14 18:01Ampotech and Buskowitz Energy Collaborate to Deliver Integrated Energy Solutions Combining Energy Efficiency, Solar and Battery Storage
[Picked up by 263 media titles]
2026-10-14 09:30
Most Read
Nuix Neo Generative AI Framework
2026-10-08 08:02
14818
LEIFRAS Co., Ltd. Reports First Half of Fiscal Year 2026 Financial Results
2026-10-08 09:50
12807
XPENG G9L Completes First Production Trial in Europe
2026-10-08 07:33
12377
